Will inter partes review speed US generic drug entry?

Nature Biotechnology 35, 1139 (2017).
doi:10.1038/nbt.4036

Authors: Jonathan J Darrow, Reed F Beall & Aaron S Kesselheim
A new extra-judicial pathway for challenging pharmaceutical patents has intensified patent challenges and helped to clear the way for earlier generic entry.

Source: Nature Biotechnology - December 8, 2017 Category: Biotechnology Authors: Jonathan J Darrow Reed F Beall Aaron S Kesselheim Tags: Feature Source Type: research